

# HCV-related HCC




Eli Zuckerman, M.D.  
Liver Unit, Carmel Medical Center,  
Technion Faculty of Medicine,  
Haifa, Israel

# Disclosures

---

- Advisory boards (international): Gilead, Abbvie, Merck, Janssen, BMS
- Consultant: Janssen, Gilead, Merck, Roche, Neopharm, Abbvie, GSK
- Advisory committees or review panels: Merck, Gilead, Janssen, BMS, Abbvie
- Speaker: Merck, Janssen, Roche, Novartis, BMS, Neopharm, GSK, Abbvie, Gilead

# Overall incidence of HCC per 100,000



■ <2.5   ■ 2.5-4.9   ■ 5-9.9   ■ 10-19.9   ■ >19.9

*UpToDate 2011:*


*High incidence  $\geq 15$  cases/100,000*

*Intermediate incidence 4-14 cases/100,000*

*Low incidence  $\leq 3$  cases/100,000*

**What is it so special  
in HCV-related HCC?  
(Epidemiology and clinical aspect)**

# Natural History and Biological Drivers of HCV-Related HCC



# 5-Year Cumulative Incidence of HCC in Patients With Cirrhosis\*


| <b>Etiology of Cirrhosis</b> | <b>5-Year Cumulative Incidence of HCC</b> |
|------------------------------|---|
| Hepatitis C virus            |   |
| Japan                        | 30%                                       |
| Europe and US                | 17%                                       |
| Hepatitis B virus            |   |
| Taiwan and Singapore         | 15%                                       |
| Europe                       | 10%                                       |
| Hereditary hematochromatosis | 21%                                       |
| Alcoholic cirrhosis†         | 8%  |
| Primary biliary cirrhosis†   | 4%  |

\*Retrospective analysis of combined data from published studies.

†In the absence of HCV and HBV viral markers.

Fattovich G, et al. *Gastroenterology*. 2004;127:S35-S50.

# Projected future incidence in HCC from HCV



# HCV-related HCC

Phylogenetic studies of HCV show that HCV began to infect:

- Japan 1920s
- Southern Europe 1940s
- North America 1960s and 1970s

HCV+ serology in patients with HCC:

- Japan 80-90%
- Italy 44-66%
- US 30-50%

Incidence of HCC in Japan is X3 than Italy and X 6 than US



## **Recommendations for the Identification of Chronic Hepatitis C Virus Infection Among Persons Born During 1945–1965**

### **Recommendations for the Identification of Chronic Hepatitis C Virus Infection Among Persons Born during 1945–1965\***

- Adults born during 1945–1965 should receive one-time testing for HCV without prior ascertainment of HCV risk.
- All persons with identified HCV infection should receive a brief alcohol screening and intervention as clinically indicated, followed by referral to appropriate care and treatment services for HCV infection and related conditions.

# HCV-related HCC



## The “baby boomers:

- Americans born between 1945 and 1965
- Represent 27% of the population of US
- Account for 75% of HCV infection in the US
- As cohort ages : cirrhosis and HCC become more prevalent

# HCV-related HCC

SEER: HCC 2003-11: 50,723 cases with HCC

BB HCC vs. pre-1945 and post-1965



- BB HCC prevalence increased **by 64%** (2003 to 2011)
- BB HCC accounts for **57.4%** of all HCC cases in the US
- BB HCC : earlier stage of HCC at diagnosis
- BB HCC: better 5y survival (vs. pre-1945)
-

# HCV-related HCC in non-cirrhotics

## HALT-C study

- Cumulative 5 years incidence of HCC in CHC: higher in patients with cirrhosis vs. bridging fibrosis (7% vs. 4.1%, **p= 0.08**)

## Dig Liver Dis 2015 (*Beaujon H, Clichy*)

- 162 pts with HCC (2000-2011)
- 137 F3-4 vs. 25 F0-2
- 16% of HCC occurred patients without advanced fibrosis
- Patients with advanced fibrosis and HCC
  - older (65 vs 62)
  - more steatosis (43% vs 20%)

# HCV-related HCC in non-cirrhotics

**Dig Liver Dis 2015 (*Beaujon H, Clichy*)**

Predictors for HCC in patients without advanced fibrosis

- Presence of HBcAb ( $p=0.044$ )
- Duration of HCV infection (0.003)

Patients without advanced fibrosis did not have more DM or steatosis

# HCV-related HCC

## Risk Factors for HCC in CHC


- HBV co-infection (odds ratio 165 vs. 17 in HCV alone)
- Alcohol (RR 2.33 in pooled M-A data, 15,000 patients)
- Metabolic syndrome
- Host genetic factors (only case-control studies)
- TNF- $\alpha$  polymorphism (TNF- $\alpha$  308, odds ratio 1.88 in Asians)
- Age (age distribution has shifted with the largest proportion in 45-60 y/o)
- Genotype 3

# HCV-related HCC

## HCC and Genotype 3

- Increased progression to advanced fibrosis/cirrhosis
- A retrospective cohort study (353 G3 patients with HCC) develop more HCC (vs. non-G3): **44% vs. 26%**
- Larger cohort studies showed that G3 had higher risk of developing cirrhosis and HCC than G1

# Viruses enhance the carcinogenic effect of alcohol





# Coffee lowers the risk for HCC



Meta-analysis 2007 Hepatology


- 10 studies, 2260 cases of HCC  
(6 case-control Southern Europe and Japan, and 4 cohort studies from Japan)
- RR of HCC in coffee drinkers: 0.54 (CC) and 0.64 (cohort)
- Increase of 1 cup of coffee per day: RR of HCC 0.75

# **HCV-related HCC**

**Is HCV-related HCC different from  
HBV-related HCC?  
(Clinical aspects)**

# Variations of HBV & HCV Prevalence in HCC: developing or developed countries

Venook, A. P. et al. Oncologist 2010;15




# HCV-related HCC

## HCV- vs. HBV-related HCC

- 31,521 new HCC cases 2003-5 (Korea): 4630 randomly studied (2785 HBV, 447 HCV)
- Incidence /100,000: HBV 20.8 vs. HCV 4.9
- HBV-related HCC: more large tumors ( $\geq 5$  cm) and PV invasion
- HCV-related HCC: multiple tumors



# HCV-related HCC

## Clinical manifestations and outcome of HCV- vs. HBV-related HCC



- HCV-related HCC: older than HBV (70+ vs. 50-59)
- Multiple tumors, smaller tumors, less outside Milan's
- Less vascular (PV) invasion

# Liver Cancer in Israel



# Hadassah-Ichilov database (6.11-9.12)

## Etiology-80 HCC Patients

| Basic Characteristics | 80 HCC patients (%) |
|-----------------------|---------------------|
| Age                   | 67.6±11             |
| Sex (male)            | 65(81)              |
| HCV                   | 42 (52)             |
| NASH                  | 20(25)              |
| HBV                   | 11(13.7)            |
| Alc comorbidity       | 10(12)              |
| Alc alone             | 3(3.7)              |
| Crypto                | 4(5)                |
| CPS A/B/C             | 65/13/2             |
| CLIP 0/1/2+           | 34/27/19            |
| BCLC A/B/C/D          | 19/23/36/2          |

# HCC-Carmel Medical Center 2010-2.2016 (n=133)

| Clinical characteristics  | HCC patients 133, (%) |
|---------------------------|-----------------------|
| Age                       | 66.5                  |
| HCV                       | 112 (84)              |
| NASH                      | 12 (9)                |
| HBV                       | 4 (3)                 |
| ALD                       | 2 (1.5)               |
| GSD                       | 2 (1.5)               |
| BCS                       | 1 (<1)                |
| Liver transplantation     | 12 (9)                |
| Resection                 | 16 (12)               |
| TACE/SIRT/RFA             | 83 (62)               |
| Symptomatic treatment     | 22 (16.5)             |
| Elevated AFP (40-118,000) | 51 (40)               |



# HCV-related HCC

## Conclusions

- **HCV is the leading etiology of HCC in the US, Europe and Japan**
- **Risk factors for CHC-HCC include DM, obesity, steatosis/NASH, alcohol, old age ,genotype 3, elevated AFP**
- **In 80-90% HCC occurs in patients with cirrhosis but may appears in patients without advanced cirrhosis (F0-2).**
- **Predictors for HCC in non-cirrhotics include HBcAb +, prolonged duration of HCV infection and other parameters**
- **Bio- or genetic markers may assist in prediction the risk for HCC in patients with chronic HCV infection**



**Thank You**